Clinical Trial Update: Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pazopanib for efficacy, safety, and quality of life in patients with advanced or metastatic renal cell carcinoma after prior checkpoint…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Pazopanib (Pazopanib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2023-03-21